Log in

Covetrus Stock Forecast, Price & News

-0.55 (-2.04 %)
(As of 12/1/2020 12:00 AM ET)
Today's Range
Now: $26.46
50-Day Range
MA: $26.34
52-Week Range
Now: $26.46
Volume596,871 shs
Average Volume1.38 million shs
Market Capitalization$3.37 billion
P/E RatioN/A
Dividend YieldN/A
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, and vitamins and supplements to wholesale and retail customers. The company also offers value-added practice solutions that include financial services, equipment repair, inventory management, and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as e-commerce, shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company, formerly known as HS Spinco, Inc., was incorporated in 2018 and is headquartered in Portland, Maine.

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Current SymbolNASDAQ:CVET



Sales & Book Value

Annual Sales$3.98 billion
Cash Flow$10.67 per share
Book Value$11.10 per share


Net Income$-1,019,000,000.00


Market Cap$3.37 billion
Next Earnings Date3/2/2021 (Estimated)
OptionableNot Optionable
-0.55 (-2.04 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for CVET and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Covetrus (NASDAQ:CVET) Frequently Asked Questions

How has Covetrus' stock been impacted by Coronavirus?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CVET shares have increased by 192.7% and is now trading at $26.46.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Covetrus?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Covetrus
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Covetrus?

Wall Street analysts have given Covetrus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Covetrus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Covetrus

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) posted its earnings results on Sunday, November, 15th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.18 by $0.08. The business had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.05 billion. Covetrus had a positive return on equity of 7.09% and a negative net margin of 1.21%. The firm's revenue was up 10.6% on a year-over-year basis. During the same period last year, the company posted ($8.56) earnings per share.
View Covetrus' earnings history

What price target have analysts set for CVET?

3 equities research analysts have issued twelve-month price targets for Covetrus' stock. Their forecasts range from $20.00 to $31.00. On average, they expect Covetrus' share price to reach $25.67 in the next year. This suggests that the stock has a possible downside of 3.0%.
View analysts' price targets for Covetrus

Are investors shorting Covetrus?

Covetrus saw a decrease in short interest in the month of October. As of October 30th, there was short interest totaling 6,050,000 shares, a decrease of 14.4% from the October 15th total of 7,070,000 shares. Based on an average daily trading volume, of 962,300 shares, the days-to-cover ratio is currently 6.3 days. Approximately 6.8% of the company's stock are sold short.
View Covetrus' Short Interest

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), The Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Mr. Benjamin Wolin, CEO, Pres & Director (Age 44, Pay $1.03M)
  • Mr. Dustin k. Finer, Chief Admin. Officer (Age 50, Pay $552.6k)
  • Ms. Georgina Wraight, Exec. VP & Pres of Global Technology Solutions (Age 45, Pay $623.24k)
  • Mr. Matthew J. Foulston, Global Chief Financial Officer (Age 55)
  • Ms. Laura J. Phillips, VP, Chief Accounting Officer & Global Controller (Age 50)
  • Mr. Steve Palmucci, Global Chief Information Officer
  • Mr. Nicholas Michael Jansen, VP of Investor Relations
  • Ms. Jamey S. Seely, Gen. Counsel & Corp. Sec. (Age 48)
  • Kiní Schoop, Director of PR
  • Mr. Anthony C. Providenti Jr., Exec. VP of Corp. Devel. (Age 53)

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Clayton Dubilier & Rice LLC (19.95%), BlackRock Inc. (11.40%), Morgan Stanley (7.28%), Freshford Capital Management LLC (3.47%), State Street Corp (2.72%) and JPMorgan Chase & Co. (2.00%). Company insiders that own Covetrus stock include Benjamin Shaw, Benjamin Wolin, Betsy S Atkins, David Christopher Dollar, Edward Mcnamara, Erin Powers Brennan, Georgina Wraight, Michael Ellis and Timothy Ludlow.
View institutional ownership trends for Covetrus

Which major investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Freshford Capital Management LLC, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Parian Global Management LP, Zuckerman Investment Group LLC, BlackRock Inc., WINTON GROUP Ltd, and State Street Corp. Company insiders that have sold Covetrus company stock in the last year include Benjamin Wolin, Edward Mcnamara, Georgina Wraight, Michael Ellis, and Timothy Ludlow.
View insider buying and selling activity for Covetrus

Which major investors are buying Covetrus stock?

CVET stock was bought by a variety of institutional investors in the last quarter, including Clayton Dubilier & Rice LLC, JPMorgan Chase & Co., GW&K Investment Management LLC, Sirios Capital Management L P, Mackay Shields LLC, Voloridge Investment Management LLC, Emerald Advisers LLC, and Emerald Mutual Fund Advisers Trust. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw, and Erin Powers Brennan.
View insider buying and selling activity for Covetrus

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $26.46.

How big of a company is Covetrus?

Covetrus has a market capitalization of $3.37 billion and generates $3.98 billion in revenue each year. The company earns $-1,019,000,000.00 in net income (profit) each year or $0.79 on an earnings per share basis. Covetrus employs 5,500 workers across the globe.

What is Covetrus' official website?

The official website for Covetrus is www.henryscheinvet.com.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.